COAG

Hemab Therapeutics Holdings, Inc. COAG

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-24.15M

Quarter to Jun 30

Free cash flow

$-22.66M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.33B total
RA CAPITAL MANAGEMENT, L.P.
$286.81M--
Novo Holdings A/S
$153.55M--
FMR LLC
$135.82M--
Capital International Investors
$132.37M--
Deep Track Capital, LP
$132.30M--
Siren, L.L.C.
$76.65M--
Avoro Capital Advisors LLC
$70.71M--
Bain Capital Life Sciences Investors, LLC
$60.60M--
JPMORGAN CHASE & CO
$42.33M--
VANGUARD CAPITAL MANAGEMENT LLC
$28.68M--
PRICE T ROWE ASSOCIATES INC /MD/
$27.40M--
DRIEHAUS CAPITAL MANAGEMENT LLC
$26.29M--
Rock Springs Capital Management LP
$21.14M--
Bellevue Group AG
$20.20M--
CITADEL ADVISORS LLC
$19.23M--
BlackRock, Inc.
$10.43M--
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$10.10M--
ExodusPoint Capital Management, LP
$8.02M--
GEODE CAPITAL MANAGEMENT, LLC
$7.78M--
BRAIDWELL LP
$5.88M--
MARSHALL WACE, LLP
$5.68M--
Woodline Partners LP
$5.51M--
Affinity Asset Advisors, LLC
$5.07M--
Ensign Peak Advisors, Inc
$4.24M--
VANGUARD FIDUCIARY TRUST CO
$4.13M--
See all 56 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/COAG

Earnings Per Share

13fpro.ai/company/COAG

Loading ratio trend…

COAG insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Hemab Therapeutics Holdings, Inc. (COAG): stock profile, AI score and financials

Hemab Therapeutics Holdings, Inc. (COAG) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. COAG is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Hemab Therapeutics Holdings, Inc. reports net income of $-24.1M, free cash flow of $-22.7M. Top institutional holders of COAG by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Novo A/S, FMR, based on the most recent SEC filings. COAG trades on the Nasdaq exchange and files with the SEC under CIK 2114044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COAG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hemab Therapeutics Holdings, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2114044 →